Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Barbara A. Zehnbauer"'
Autor:
Barbara A. Zehnbauer
Publikováno v:
The Journal of molecular diagnostics : JMD. 24(5)
Publikováno v:
American journal of clinical pathology. 157(4)
Objectives Diversity of laboratory-developed tests (LDTs) using next-generation sequencing (NGS) raises concerns about their accuracy for selection of targeted therapies. A working group developed a pilot study of traceable reference samples to measu
Publikováno v:
Critical care medicine. 48(2)
Autor:
Barbara A, Zehnbauer
Publikováno v:
The Journal of molecular diagnostics : JMD. 21(6)
This editorial highlights 20 years of JMD defining professional practice.
Autor:
Timothy G. Buchman, Ramzy H. Rimawi, Yoram Vodovotz, Timothy R. Billiar, Allan D. Kirk, Barbara A. Zehnbauer, Eric A. Elster
Publikováno v:
Critical Care Medicine. 44:1635-1638
Precision medicine aims to identify, select, and schedule therapies that are most likely to yield a favorable outcome for an individual patient (1). Conventional and precision approaches may differ according to the choices of drug, device or operatio
Autor:
Ira M. Lubin, Lee-Jun C. Wong, Rakesh Nagarajan, Birgit Funke, David P. Bick, Shashikant Kulkarni, Himani Bisht, Zoya Dimitrova, Richard B. Resnick, Pavel Skums, David Dimmock, Fiona Hyland, Christopher E. Mason, Perry G. Ridge, Nabil Hafez, Tobias Mann, Nazneen Aziz, Sarah F. Bennett, Shaw R. Gargis, Elizabeth A. Worthey, Amy S. Gargis, Heidi L. Rehm, Marc L. Salit, Ruth Ann Luna, Timothy K. McDaniel, David S. Campo, Lisa V. Kalman, Deanna M. Church, Lilia Ganova-Raeva, Justin M. Zook, Karl V. Voelkerding, Madhuri Hegde, Sivakumar Gowrisankar, Duncan MacCannell, Tina Hambuch, Megan R. McCluskey, Cristina da Silva, John Barnes, Jeffrey Reid, Barbara A. Zehnbauer
Publikováno v:
Nature Biotechnology. 33:689-693
Autor:
Barbara A. Zehnbauer, Ira M. Lubin, Shannon D. Barker, Sue Richards, Iris Schrijver, Lisa V. Kalman, Desirée du Sart, Mario Pazzagli, Rob Elles, Wayne W. Grody
Publikováno v:
Archives of Pathology & Laboratory Medicine. 137:983-988
Participation in proficiency testing (PT) or external quality assessment (EQA) programs allows the assessment and comparison of test performance among different clinical laboratories and technologies. In addition to the approximately 2300 tests for i
Autor:
Ute Geigenmüller, Megan Manion, Jason D. Merker, David Dimmock, Madhuri Hegde, Matthew J. Ferber, Barbara A. Zehnbauer, Martin G. Reese, Ira M. Lubin, Justin M. Zook, Joanne M. Yeakley, Daniel H. Farkas, Tina Hambuch, Teri A. Manolio, Meredith W Berry, Karl V. Voelkerding, Thomas Lenk, Sarah F. Bennett, Bin Chen, Lisa V. Kalman, Soma Das, Lilia Ganova-Raeva, Philip L. F. Johnson, David P. Bick, Manohar R. Furtado, John G. Compton, Elaine R. Mardis, Amy S. Gargis, Sandra J Gunselman, Elaine Lyon, Birgitte B. Simen, Heidi L. Rehm, Richa Agarwala, Mangalathu S. Rajeevan, Birgit Funke, CS Jonathan Liu, Ephrem L H Chin, Shashikant Kulkarni, Fei Lu, Andrew Kasarskis
Publikováno v:
Nature Biotechnology. 30:1033-1036
Autor:
Eizo Watanabe, Barbara A. Zehnbauer, Hiroyuki Hirasawa, Timothy G. Buchman, Shigeto Oda, Yasunori Sato
Publikováno v:
Cytokine. 60:249-256
Purpose Management of sepsis in critically ill patients remains difficult and requires prolonged intensive care. Genetic testing has been proposed as a strategy to identify patients at risk for adverse outcome of critical illnesses. Therefore, we wis
Autor:
Hang Wu, May D. Wang, Karlyn K. Wilson, Julie R. Taylor, Chih-Wen Cheng, Pamela J. Thompson, Barbara A. Zehnbauer
Publikováno v:
EMBC
Conf Proc IEEE Eng Med Biol Soc
Conf Proc IEEE Eng Med Biol Soc
Patients with certain clotting disorders or conditions have a greater risk of developing arterial or venous clots and downstream embolisms, strokes, and arterial insufficiency. These patients need prescription anticoagulant drugs to reduce the possib